Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes
Bagsværd, Denmark, 5 December 2016 – Novo Nordisk today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, for the treatment of adults with type 2 diabetes.
The submission is based on the results from the SUSTAIN clinical trial programme, which included more than 8,000 adults with type 2 diabetes. In the SUSTAIN programme, once-weekly semaglutide was studied in combination with oral-antidiabetic agents and basal insulin. Semaglutide demonstrated statistically significant and sustained blood glucose control compared to sitagliptin, exenatide extended-release, once-daily insulin glargine U100 and placebo. Furthermore, the cardiovascular outcomes trial, SUSTAIN 6, demonstrated a statistically significant cardiovascular risk reduction compared to placebo, as add-on to standard of care in patients with high cardiovascular risk. In addition, semaglutide demonstrated statistically significantly greater reductions in mean body weight versus comparators.
Across the SUSTAIN clinical trial programme, once-weekly semaglutide had a safe and well tolerated profile with the most common adverse event being nausea.
“Achieving blood glucose control, weight loss and reducing the risk of cardiovascular events remains a significant challenge for adults with type 2 diabetes,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We are excited with this regulatory filing, as results from the SUSTAIN programme show that once-weekly semaglutide has the potential to further improve the treatment of adults with type 2 diabetes.”
About semaglutide
Semaglutide is a new once-weekly analogue of human GLP-1 that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake. Novo Nordisk intends to make once-weekly semaglutide available in a prefilled delivery device based on the same technology platform as FlexTouch®.
Read the full announcement
Further information
| Media: | ||
| Katrine Sperling | +45 4442 6718 | [email protected] |
| Ken Inchausti (US) | +1 609 786 8316 | [email protected] |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | [email protected] |
| Melanie Raouzeos | +45 3075 3479 | [email protected] |
| Hanna Ögren | +45 3079 8519 | [email protected] |
| Anders Mikkelsen | +45 3079 4461 | [email protected] |
| Kasper Veje (US) | +1 609 235 8567 | [email protected] |
Company announcement No 86 / 2016
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/d2f719e1-d69f-4918-ae7e-48fc6b731183
